Filing Flows › Entrada Therapeutics (TRDA) › Guidance & outlook

Entrada Therapeutics (TRDA) guidance and outlook

Entrada Therapeutics' 10-Q filed Nov 5, 2026 makes 41 forward-looking statements.

Guidance and outlook

41 statements; tone +0.20 (−1 all cautious, +1 all confident); 10 hedged.

Forward-looking statements, 10-Q filed Nov 5, 2026

We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible .
In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with Vertex on track to share interim results in the second half of 2026.
In addition to the ELEVATE-45-201 Cohort 1 results included in this Quarterly Report, we anticipate additional ELEVATE-44-201 Cohort 1 open-label data by the end of 2026.
We anticipate topline data from Cohort 2 of our ELEVATE-44-201 multiple ascending dose ("MAD") trial in the first quarter of 2027 and to report our Cohort 2 ELEVATE-45-201 MAD data in the first half of 2027.
When combined, we estimate that there are over 11,500 patients in the U.S. and Europe that carry mutations amenable to Entrada's current exon skipping programs.
Each of these programs utilize the same endosomal escape vehicle, and as such, we anticipate initial data readouts from any one of the candidate clinical trials to provide critical insights for the rest.
Enrollment is complete for Cohort 2 of the global Phase 1/2 MAD portion of the study at the increased dose of 12 mg/kg, and we expect to report topline results including safety, exon skipping, dystrophin and functional readouts in the first quarter of 2027.
We anticipate seeing an increase in dystrophin and improvements in functional responses as we increase dosing amounts in the second and third cohorts.
We also intend to open an expansion cohort to increase the number of participants treated in the ELEVATE-44-201 study, as this study has been designed to support an accelerated approval in the U.S.
pharmacokinetic and pharmacodynamic data from our lead programs in the U.K. and EU, we will continue to engage with the FDA and will provide an update on the clinical study design and timing when appropriate.
We expect ENTR-601-45, at higher doses, has the potential to be both best in class and to be the first PMO-conjugate to generate clinically meaningful data in a population where low single digit competitive dystrophin production has been observed to date.
ELEVATE-50-201 and ENTR-601-51 : We expect to submit additional regulatory applications following a review of data from the ongoing trials of our lead programs.

Entrada Therapeutics' latest quarter

Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.

Questions

What does Entrada Therapeutics expect?

We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible . In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with Vertex on track to share interim results in the second half of 2026. In addition to the ELEVATE-45-201 Cohort 1 results included in this Quarterly Report, we anticipate additional ELEVATE-44-201 Cohort 1 open-label data by the end of 2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.